Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors

Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part III

“…A group from China engineered Staidson protein-0601 (STSP-0601), a factor X activator from RVV and showed that it has the potential to be used as a hemostatic treatment of patients with hemophilia and inhibitors. 19 The issue then includes some correspondence. First, Goh and colleagues review the condition known as hematohidrosis in 15th Century Renaissance Art and also provide a review of modern literature.…”

Russell Viper Venom: A Journey from the Bedside to the Bench and Back to the Bedside

“…30 Liu et al performed preclinical and phase 1 studies of this factor X activator in patients with hemophilia A or B who have inhibitors. 30 They treated 16 patients with STSP-0601 at increasing doses and showed increased thrombin generation and shortening of the aPTT dose-dependently with no Fig. 1 Historical timeline for Russell's viper from its discovery to the use of its venom as a hemostatic agent in hemophilia, diagnostic test for antiphospholipid syndrome, and recently its engineered derivative as treatment for hemophilia with inhibitor.…”

“…30 Liu et al performed preclinical and phase 1 studies of this factor X activator in patients with hemophilia A or B who have inhibitors. 30 They treated 16 patients with STSP-0601 at increasing doses and showed increased thrombin generation and shortening of the aPTT dose-dependently with no thromboembolic complications. 30 Although further studies are required, RVV-derived factor X activation may become another tool in the treatment armamentarium for patients with hemophilia and inhibitors.…”

“…30 thromboembolic complications. 30 Although further studies are required, RVV-derived factor X activation may become another tool in the treatment armamentarium for patients with hemophilia and inhibitors.…”

“…A group from China engineered Staidson protein-0601 (STSP-0601), a factor X activator from RVV and showed that it has the potential to be used as a hemostatic treatment of patients with hemophilia and inhibitors. 30 Liu et al performed preclinical and phase 1 studies of this factor X activator in patients with hemophilia A or B who have inhibitors. 30 They treated 16 patients with STSP-0601 at increasing doses and showed increased thrombin generation and shortening of the aPTT dose-dependently with no thromboembolic complications.…”